2000
DOI: 10.1002/(sici)1098-2388(200003)18:2<100::aid-ssu3>3.0.co;2-9
|View full text |Cite
|
Sign up to set email alerts
|

Lung cancer chemoprevention

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
9
0
2

Year Published

2003
2003
2015
2015

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(11 citation statements)
references
References 41 publications
0
9
0
2
Order By: Relevance
“…Unfortunately, the desired effects of these therapies may be offset by undesirable inflammatory reactions that limit therapy in humans. To reduce the undesirable effects, dietary supplements and anti-oxidants have been increasingly utilized [1][2][3]. They are postulated to reduce the toxic effects of therapy, reduce oxidant stress and enhance the host immune response to some cancers.…”
Section: Introductionmentioning
confidence: 99%
“…Unfortunately, the desired effects of these therapies may be offset by undesirable inflammatory reactions that limit therapy in humans. To reduce the undesirable effects, dietary supplements and anti-oxidants have been increasingly utilized [1][2][3]. They are postulated to reduce the toxic effects of therapy, reduce oxidant stress and enhance the host immune response to some cancers.…”
Section: Introductionmentioning
confidence: 99%
“…In both in vivo and in vitro studies, SeM has emerged as one of the most potent agents evaluated as a countermeasure for HZE particle-induced oxidative stress (5). Non-toxic levels of SeM have been shown to have cancer chemopreventive activity (6)(7)(8)(9)(10). SeM is the form of selenium that has been chosen by the National Cancer Institute (NCI) for current studies of selenium as a cancer preventive agent.…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, clinical trials with retinoids and/or Vitamin A derivatives have yielded mixed results. For example, three placebo-controlled trials with etretinate, isotretinoin, and fenretinide, respectively, have shown no improvements in rates of reversal of metaplasia, as recently reviewed by Khuri and Lippman [7]. At the same time, an adjuvant trial in patients with early-stage, resected NSCLC found that retinyl palmitate reduced the time to second tobacco-related primary cancers [8].…”
Section: Introductionmentioning
confidence: 99%